Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker-Reference-Cited by-同舟云学术

Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker

Published:2012-12-18 Issue:5 Volume:34 Page:769-771
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Antonelli T.,Tomasini M. C.,Castellazzi M.,Sola P.,Tamborino C.,Ferraro D.,Ferraro L.,Granieri E.

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Neurology (clinical),Dermatology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10072-012-1265-9.pdf

Reference16 articles.

1. Compston A, Coles A (2002) Multiple Sclerosis. Lancet 359:1221–1231

2. Teunissen CE, Dijkstra C, Polman C (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4(1):32–41

3. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF (2008) Cognitive impairments in relapsing–remitting multiple sclerosis: a meta-analysis. Multiple Scler 14(9):1250–1261

4. Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE, Krupp LB (2006) Effect of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 245:127–136

5. Christodoulou C, MacAllister WS, McLinksey NA, Krupp LB (2008) Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs 22(2):87–97

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-inflammatory Therapy by Cholinergic and Purinergic Modulation in Multiple Sclerosis Associated with SARS-CoV-2 Infection;Molecular Neurobiology;2021-07-11

2. Pharmacotherapy in multiple sclerosis-induced cognitive impairment: A systematic review and meta-analysis;Multiple Sclerosis and Related Disorders;2020-11

3. Cholinergic and purinergic systems: A key to multiple sclerosis?;Journal of the Neurological Sciences;2018-09

4. Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta-analysis;Neuroscience & Biobehavioral Reviews;2018-03

5. Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis;PLOS ONE;2015-04-02